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Objective 
To establish an animal model to study the effect of transcatheter 
intraarterial embolization with lipiodol-ethanol mixture in cirrhotic 
livers 
Materials and Methods 
The study was divided into two groups, a development study and a pilot 
study. 72 male Wistar rats were involved in this study. Of these rats 56 
were treated with thioacetamide to induce cirrhosis. Ten rats were lost. 
Fifty rats were necessary to perfect the necessary skills and learn what 
new problems the presence of cirrhosis would add to the procedure 
already established in healthy rats. The final pilot study group consisted 
of six normal rats and six cirrhotic rats. A formulation of lipiodol-
ethanol mixture (LEM) was used comprising lipiodol and ethanol in a 
four to one by volume ratio. 
LEM was administered intra-arterially into the right lobe of all the rats 
with direct catheterization of the gastroduodenal artery in a retrograde 
fashion using a one-French silicon tubing. Appropriate flow diversion 
was achieved with silk ties. Lipiodol-ethanol mixture administration was 
performed using small aliquots and was monitored with stringent 
microscopic observation over the hepatic artery and liver surface 
through the laparotomy wound. Installation was stopped when there was 
flow cessation and colour change. The gastroduodenal artery was then 
ligated, the laparotomy was closed and the rats were kept alive for 
fourteen days. Radiographs were taken of the rats on day 0 and day 14 
after LEM administration. Blood was taken for liver function tests 
before LEM administration and fourteen days afterwards. Blood test 
results were analysed with Kruskal-Wallis test and Mann-Whitney's 
test. 
Based on the intra-arterial distribution of the LEM within the right lobe, 
the size of the embolized right lobe of the rats was measured from 
frontal view and lateral views of radiographs taken on day 0 and on day 
14. The percentage reduction in right lobe dimension fourteen days after 
embolization was compared between the cirrhotic and normal groups. 
The embolized right lobes were taken out on day 14 and were examined 
histologically for the degree and extent of infarction. 
iii 
Results 
1. A cirrhotic rat model was established and its particular problems 
recorded. 
2. All twelve rats survived fourteen days after lipiodol-ethanol mixture 
administration. The radiographs showed peripheral distribution of 
LEM within the hepatic vasculature in the right lobe of all rats, 
which persisted on day 14. There was a marked reduction in volume 
of right lobe fourteen days after LEM treatment, with an average 
reduction of 63.4 土 16.9o/o and 59.4 土 20.6o/o observed in both the 
normal group and the cirrhotic group respectively. This difference 
was not statistically significant. 
3. There was no radiographically visible embolization of the lung by 
the lipiodol. 
4. On day 14，histological study showed complete non-inflammatory 
true vascular infarction in 100% of the right lobe in both groups. 
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Go 门 elusions 
1 • An animal model to study the effect of transcatheter intraarterial 
embolization with lipiodol-ethanol mixture in a live cirrhotic rat 
model was successfully established. 
2. Selective hepatic lobar ablation with intra-arterial administration 
of lipiodol-ethanol mixture can be achieved in both the normal 
liver and cirrhotic liver of rats. 
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結論 
(一)成功地建立了一個動物模範，以硏究經導管方式把澳油 
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1 Introduction 
Transcatheter intra-arterial hepatic lobar or segmental ablation with a 
lipiodol (ethiodol)-ethanol mixture has been shown to be an effective 
treatment option for hepatocellular carcinoma (1). Ablation of the whole 
hepatic segment or lobe containing the tumor offers a theoretical 
advantage of complete tumor eradication with a sufficient safety margin, 
which includes the tumor capsule and any adjacent satellite nodules. 
More importantly, during the treatment process, the tumor is kept 
untouched from direct instrumentation or surgical manipulation, which 
potentially may lead to tumor cell dissemination. (1) 
It has been shown that communication between the hepatic artery and 
the portal vein occurs through the peribiliary venous plexus. This 
permits drainage of arterial embolizing agents such as lipiodol, silicone 
rubber solution and micro-particles into the portal venules (2). 
Therefore, intra-arterial embolization of the liver with conventional 
embolizing agents including lipiodol can only result in an incomplete 
and transient embolization effect. In contrast, an ablative agent such as a 
lipiodol-ethanol mixture when administered intra-arterially through the 
hepatic artery can produce dual hepatic arterial and portal venous 
embolization, resulting in complete devascularization and infarction of 
the respective segment. The proportion by volume of lipiodol to ethanol 
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that produces the best results in the normal liver has been shown to be 4 
to 1 (3). 
The ethanol component within the lipiodol-ethanol mixture (LEM) 
enhances long-lasting embolization by causing endothelial damage, 
fibrinous and polymorphonuclear leukocytic thrombosis of the arteriolar 
lumen and coagulative necrosis of the adjacent hepatic parenchyma in 
the acute stage, and fibrosis in a chronic stage (4). 
As hepatocellular carcinoma is commonly associated with liver 
cirrhosis, it would be important to understand whether transcatheter 
lobar ablation with LEM in cirrhotic livers is as effective and safe as it is 
in normal livers. As the pre-clinical experiments concerning LEM 
carried out so far were based on normal livers and not cirrhotic livers, 
which being already diseased may not behave in a similar manner and 
allow passage of such substances into the systemic circulation and the 
liver itself may not be able to withstand the damage as well as the 
normal livers. The author's aims were to establish an experimental 
animal model that would be useful for the evaluation of the 
effectiveness and safety of intra-arterial LEM in cirrhotic livers. 
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2 Hypothesis 
It is hypothesized that an animal model can be established in rats for the 




To establish an animal model useful for studying the effect of 
transcatheter intraarterial embolization with lipiodol-ethanol mixture in 
cirrhotic livers. 
4 
4 Clinical implications 
Hepatocellular carcinoma (HCC) is a common cancer worldwide and 
the situation is similar in Hong Kong (5). Liver cirrhosis is commonly 
associated with HCC (6). Cirrhosis is a cause of liver function 
impairment. Impaired liver function due to liver cirrhosis is a major 
factor limiting the feasibility of treatment provision to patients suffering 
from HCC (6). 
Transcatheter hepatic lobar ablation with a lipiodol-ethanol mixture is 
an intraarterial treatment option for hepatocellular carcinoma (7). 
However, it is unknown whether this treatment can be well tolerated by 
cirrhotic patients. 
By establishing this animal model, it is hoped that this could provide a 
basis for future research on LEM treatment of HCC in cirrhotic livers. 
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5 Methodology 
This study was divided into two main parts; Firstly, to establish whether 
there were any new problems arriving from applying the LEM 
administration technique to cirrhotic rats, the model development group, 
and secondly, to carry out a pilot study to test the feasibility and 
usefulness of this animal model. 
72 twelve weeks old male Wistar rats were recruited for this study. Of 
these, 56 out of the 72 rats had induction of liver cirrhosis by repeated 
intraperitoneal injection of 4 mg per kg of thioacetamide 
(Thioacetamide [Ethanethioamide], Aldrich Brand, formerly SIGMA 
product, P.O. Box 14508, St. Louis, MO 63178 U.S.A.) three times a 
week for six consecutive weeks. 50 rats (10 normal, and 40 cirrhotic) 
were assigned to the model development group. Six out of the 46 
cirrhotic rats were randomly recruited into the pilot study group. 
Another six healthy rats were recruited at random from the 16 healthy 
rats into the pilot study group. Thus, altogether, twelve rats were 
recruited into the final pilot study group. 
62 rats including the model development group and the pilot study 
group at about 18 weeks of age, had a laparotomy and selective injection 
of intra-arterial lipiodol-ethanol mixture (Lipiodol® ultra-fluide, ethyl 
esters of the iodized fatty acids of poppy-seed oil; contains 37% by 
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weight of iodine: 16 me J. Chaptal F-93600, Aulnay-sous-Bois France; 
and ethanol, ethyl alcohol, 200 proof. Quantum Chemical Corporation, 
Tuscola, III) of the right lobe of liver which was selectively embolized 
with the lipiodol-ethanol mixture through the gastroduodenal artery 
(GDA). 
Radiographs with high definition films were taken of the abdomen of 
each of the final pilot study group rats on day 0 and day 14 after LEM 
treatment, to show the distribution pattern of LEM within the rat liver 
and to observe the change in volume of the embolized lobe as outlined 
by LEM, for all the twelve rats. 
Blood specimens were taken from the lower limb of the twelve rats 
before LEM treatment and on day 0 and day 14 after LEM treatment. 
Blood specimens then underwent the following liver function test: 
serum albumin, bilirubin, alkaline phosphatase and alanine 
aminotransferase. 
On day 14 after LEM embolization, about 20 weeks old when blood 
taking and radiological examination were completed, all the twelve rats 
were euthanaised. The liver of each rat was examined grossly and the 
embolized right lobe was taken out for histological analysis. 
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5.1 Materials 
5.1.1 Study subjects 
The experiment began with 72 rats. All the rats were active and healthy 
male Wistar rats of approximately equal ages and body weight (about 
300gm per each), and they were selected at random. Only male rats were 
recruited to avoid unwanted propagation. They were fed with standard 
food pellets and tap water ad libitum. All rats were kept at the same room 
under the same conditions, with the normal rats and cirrhotic rats 
separated from each other in the animal house on the G/F of the Clinical 
Science Building of the Prince of Wales Hospital. 
Of the 72 rats, 56 of them were induced with liver cirrhosis (Please refer 
to page 6; section 5，on the details of the techniques on drug-induced liver 
cirrhosis on rats). This technique is known to result in death or severe 
illness in a significant proportion of the rats, and in this series, ten of 
them were lost because of this. 
According to the experience of some centers in the United States that 
conducting similar experiments on rats, it usually takes more than three 
months and over 50 rats to acquire the necessary skills of successful 
hepatic artery catherization and LEM injection (2，3). Therefore, 50 rats 
(40 cirrhotic and 10 normal) were set aside to practice and to perfect the 
technique, and twelve rats (six cirrhotic and six normal) were set aside for 
the final pilot study. 
8 
• 9 
r a t s I ^ H 
(Pilot study ! 
^ SO r^ats 
H R i n f l : (Cirrhosis) 
• H t a i l H I 
^ ^ ^ ^ ^ ^ ^ • ； 1 rats j H I H rats f B rats 
(Lost) I j m m ^ (Normal) i • (Cirrhosis) 
5.1.3 Instruments 
A low power dissecting microscope 8x-50x (Brand name: Olympus 
OME, Japan) was used for dissection procedures and control of LEM 
injection. A set of micro-dissecting instruments {Microsurgical 
Instruments, Chen-He Microsurgical Instruments Factory, Duan Tang 
Town Wu Jia-Ningbo, China [Microsurgical Instruments, Chen-He 
Microsurgical Instruments Factory, Ningbo, China]} including two pairs 
of sharp forceps, two pairs of pointed forceps, three pairs of artery 
forceps and five pairs of haemostatic forceps, was used. Centrifuge 
equipment was employed for extracting blood serum from the blood 
specimens. 
5.1.4 Consumables 
Strings of silastic laboratory tubing (SILASTIC® Laboratory Tubing, 
0.30mm x 0.64mm: Dow Coming Corporation. Midland. Michigan. 
U.S.A.) were cut into equal length of about 3cm. (Figure 1) 27G injective 
needle tips were modified as connectors used for connecting the silastic 
tubing to Icc glass syringes for injection of LEM (Figure 2). Other 
consumables included silk tie stitches, cotton packing-gauze, swab sticks 
for removing blood during the operation, normal saline drops (at 37°C)， 
and vaseline ointment used for blood taking. 
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5.1.5 Embolic agents 
Lipiodol ultra-fluide and ethanol (99% ethyl alcohol) were used for 
preparation of the lipiodol-ethanol mixture. 
5.1.6 Anaesthetic drugs 
5mg per kg of xylazine (Xylazine®, Alfasan, Barwoutswaarder 13; 3449 
HE Woerden, Holland) and 80mg per kg of ketamine (Ketamine®， 
Alfasan, Barwoutswaarder 13; Woerden, the Netherlands) were used for 
preparing the mixture for anaesthesia. (Please refer to page 55; table 9 for 
the protocol on the use of anaesthetic drugs of xylazine and ketamine.) 
0.3mg per kg of buprenorphine (TEMGESIC® injection; Schering-
Plough, brand of buprenorphine hydrochloride, Reckitt & Colman 
Overseas] Ltd.) was used for pain relief in the rats for the initial 24 hours 
after LEM administration. 
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Figure 1 Picture of the 1 -F SILASTIC® laboratory tubing 
I Silastic 
Figure 2 Picture of silastic tubing being connected to a 1cc 
syringe containing LEM 
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5.2 Study method 
5.2.1 Selection of rats 
72 male Wistar rats, around 300gms in weight were recruited at random 
from the breeding facility of the Chinese University of Hong Kong. 56 of 
these were subjected to intraperitoneally injected thioacetamide to induce 
liver cirrhosis. 10 were lost because of illness during the course of drug-
induced liver cirrhosis. 10 out of the 16 normal rats and 40 out of the 
remaining 46 cirrhotic rats were used to acquire the skills of hepatic 
artery catheterization and LEM injection. 12 rats were set aside for the 
final pilot study, divided equally into a normal group and a cirrhotic 
group. 
5.2.2 Hepatic artery catheterization 
The rat was fixed onto a plastic board at its four limbs with adhesive 
tapes after it was deeply anaesthetized with an intra-peritoneal injection 
of 50 mg per kg of the mixture of xylazine and ketamine. The abdomen 
was shaved with an electric shaver and then a midline incision was made. 
Bilateral abdominal traction was achieved with artery forceps or 
retractors. The xiphistemum was removed with a pair of scissors after 
being held with an artery forceps. Intestines were removed gently and 
placed on the right hand side. Small gauze pads soaked with normal 
saline at 40°C were used to retract the liver. Dissection was carried out 
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under a dissecting microscope to identify the common bile duct (CBD)， 
the portal vein (PV) and the gastroduodenal artery (GDA). The fatty 
tissue between CBD and PV was dissected for isolation of the GDA with 
pointed and curved forceps (Figure 5). The GDA was isolated with 
pointed forceps from its origin on the left side to its bifurcation on the 
right side. A double knot tie of silk thread was made just at the 
bifurcation of the GDA with pointed forceps and curved forceps and held 
with artery forceps (Figure 6，10). A silk thread loop was placed at the 
origin of GDA with a pointed forceps and curved forceps and held with 
artery forceps (Figure 6, 10). A silk thread with single preparatory knot 
was placed just proximal to the bifurcation of the GDA (Figure 10). A 
small incision was made at the anterior wall of the main trunk of the 
gastroduodenal artery near to its bifurcation with sharp forceps and a pair 
of microscissors (Figure 7, 11). The rim of the arterial incision wound 
was held open with sharp forceps. The lumen of the GDA was widened 
with a limb of curved forceps. The 1-F silastic tubing was held with 
curved forceps 1 -2mm from its tip for threading into the artery. The artery 
was then catheterized with the silastic tubing in a retrograde direction 
with the tip placed close to but inferior to the origin of the proper hepatic 
artery (Figure 12，13). By tightening the preparatory knot of the silk 
thread just proximal to the bifurcation, the GDA was tied onto the 
catheter with two knots, so that the intra-arterial portion of the tubing was 
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fixed within the gastroduodenal artery and the tubing was wedged within 
the artery (Figure 9，12). One of the bifurcated branches of the proper 
hepatic artery that supplies the right lobe of the liver was identified and 
the other branch that supplies the rest of the liver was isolated and tied to 
occlude the vessel temporarily with a silk thread. The patency of silastic 
tubing was then tested with a gentle aspiration to show free flow of blood. 
5.2.3 LEM administration 
The LEM was prepared just before injection by vigorous shaking of the 
two components within a 1ml syringe until a uniformly clear emulsion 
was obtained. The syringe was then connected to the silastic tubing with a 
modified 27gauge needle. Under microscopic control, the LEM was 
administered slowly and in small aliquots into the proper hepatic artery, 
to be carried into the right lobe of liver by blood flow from the common 
hepatic artery, until flow stagnation was observed in the hepatic artery 
branch to the right lobe. The temporary tie at the hepatic artery supplying 
the other lobes was then released. Afterwards, the silastic tubing was 
removed while the gastroduodenal artery was ligated with silk threads 
above and below the incision wound. The abdominal wound was then 
repaired with a 4-0 polypropylene suture and the rat was allowed to 
recover from anaesthesia. Antibiotics were not given. 
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5.2.4 Animal care and monitoring 
0.3mg per kg of buprenorphine (Please refer to page 11; section 5.1.6 for 
the details on the brand name and the manufacturer of buprenorphine) 
was injected to the rats at 2-3 hourly intervals for 24 hours to 48 hours 
post-surgery for pain relief. The response, breathing pattern and urine 
output of the rats were observed and closely monitored throughout the 
process of dissection. Additional small doses of anaesthetic drug was 
given when necessary, with the total dose not exceeding the upper limit 
allowed for each rat as mentioned on page 80; section 7.6 of the 
Discussion. 
The rats would be euthanaised by using an overdose of about 150mg per 
kg of the mixture of xylazine and ketamine if they appeared to be in pain 
or if there was severe uncontrollable internal bleeding during operation. 
In the final pilot study, all the twelve rats tolerated with the LEM 
treatment and the operations very well. No rat required euthanasia 
because of the above situations. 
After operation, the rats were closely monitored for signs of illness and 
suffering. Rats that became inactive and unwilling to eat or drink for 
more than two days were caged separately to reduce any stress caused by 
the other rats. They would be euthanaised by using an overdose of about 
ISOmg per kg of the mixture of xylazine and ketamine given 
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intraperitonedly if they were considered to be suffering by the 
experienced animal keeper. 
5.2.5 Radiographic examination 
Radiographic examination was performed on day 0 just after LEM 
administration when the abdominal wound had been closed but the rat 
had not yet recovered from anaesthesia. On day 14，radiography was 
performed after the rat was given an overdose of the mixture of xylazine 
and ketamine intraperitoneally in preparation for the harvesting of the 
liver. The rat was radiographed with a postero-anterior view and a cross 
table lateral view, which included graduated lead markers to facilitate 
calibration and measurement, with the center at the upper abdomen, and 
the lungs included, using high-definition radiographic films. A lead ruler 
(GLOBE®, Japan.) was radiographed side by side with the rat on all the 
radiographs to serve as a calibration scale (Figure 3, 4). 
The dimensions of the right lobe were defined on the radiographs by 
LEM opacification. The radiographic postero-anterior view (PA view) 
and cross-table lateral view were used to provide measurements in three 
dimensions of the embolized right liver lobe, which were anterio-
posterior diameter (APD), transverse diameter (TD) and the maximum 
short axis diameter in the transverse plane (T). Since the shape of the 
right liver lobe of the Wister is very similar to that of a prism, the volume 
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of the right liver lobe was calculated as if it were a prism according to the 
following formula: 
Volume of embolized liver (mm )^ = APD (mm) x 
TD (mm) x T (mm) x 1/2 
Before the measurement, the instrument used for measurement was 
calibrated with the scale of the lead ruler on the radiographs. In order to 
reduce the measurement error (8), each measurement was a mean of 
three. Measurement of the sizes of livers was carried out on two separate 
occasions to further reduce the measurement error. As only one observer 
(I myself) was involved in the process of all the measurements, inter-
observer variability was eliminated. 
The volume of the right liver lobe of all the twelve rats on day 0 and on 
day 14 after LEM treatment was calculated. The change in right lobe 
volume and the percentage change in right lobe volume over 14 days after 
LEM were calculated for the twelve rats. The findings of volume change 
and percentage volume change of right lobe after LEM for the cirrhotic 




Figure 3 Radiograph demonstrating how TD (transverse 
diameter) and T (maximum short axis diameter of 
the transverse plane) of the right liver lobe were 
measured 
mi^KMKt 
Figure 4 Radiograph demonstrating how APD (anterior-
posterior diameter) was measured. A lead ruler 
was used for calibration purpose 
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5.2.6 Blood tests for liver function 
Blood tests for liver function were performed for all rats in both groups 
on the day before LEM treatment and on day 0 and day 14 after LEM 
treatment. Blood samples of 0.5ml in volume were collected by slow 
aspiration from the lower limb of the rats after topical application of 
vaseline and needle puncture. The tests included the measurement of 
serum albumin, bilirubin, alkaline phosphatase (ALP), and alanine 
aminotransferase (ALT). All blood specimens were sent for liver function 
test at the Department of Chemical Pathology of the Chinese University 
of Hong Kong. 
5.2.7 Liver specimen examination 
On day 14，rats of both groups were euthanaised with an overdose of 
150mg per kg of the mixture of xylazine and ketamine injected 
intraperitoneally. After radiography and blood taking, the livers were 
examined grossly through laparotomy for appearance, size and 
compatibility with radiographic findings. The livers were then taken out. 
The right lobes were preserved with 10% formalin and embedded in 
paraffin. The specimens were then sectioned at 5|Jm thickness at 3mm 
intervals and stained with hematoxylin and eosin for histological 
examination to study the degree and extent of infarction. One pathologist 
carried out the histological assessment of all specimens in this research in 
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order to eliminate inter-observer variability (19). All the specimens were 
assigned with different numbers. Throughout the research, the pathologist 
was blinded to the real identity of the specimens to avoid bias. However, 
the presence of cirrhosis was obvious in all those rats that caused bias. 
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5.3 Venues of the research 
Different parts of the research were conducted in four different places 
within three different departments of the Chinese University of Hong 
Kong at the Prince of Wales Hospital, including the Department of 
Diagnostic Radiology & Organ Imaging, the Department of Surgery and 
the Department of Anatomical and Cellular Pathology. All the 
experiments on rats were carried out at the Lee Hysan Clinical Research 
Laboratory (Address: 7/F, Clinical Science Building, Prince of Wales 
Hospital.). Before and after the LEM treatment, live rats were incubated 
at the Animal House of the Prince of Wales Hospital (Address: G/F, 
Clinical Science Building, Prince of Wales Hospital). All the radiographs 
of the rats were acquired at the Department of Diagnostic Radiology & 
Organ Imaging by myself. Blood specimens and tissues specimens of the 
rats were taken by myself but analysed at the Department of Chemical 
Pathology and the Department of Anatomical and Cellular Pathology 
respectively (Address: 1/F, Clinical Science Building, Prince of Wales 
Hospital). 
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5.4 Data acquisition 
Four catalogues of data were collected: 
5.4.1 Serological data on the liver function. 
1. Serum albumin 
2. Bilirubin 
3. Alkaline Phosphatase (ALP) 
4. Alanine Aminotransferase (ALT)/ 
formerly Serum Glutamic-Pyruvic Transaminase (SGPT) 
5.4.2 Radiological data of the embolized liver lobe. 
1. Intra-arterial distribution of lipiodol-ethanol mixture 
2. Extra-arterial distribution of lipiodol-ethanol mixture 
3. Measurement on the volume of the embolized right 
lobe of liver. 
5.4.3 Morphological data of the liver. 
1. Colour and appearance of the embolized liver lobe. 
2. Changes on the volume of the embolized liver lobe. 
5.4.4 Histological data of the embolized liver lobe. 
1. True vascular infarction (non-inflammation) 
2. Acute necrotizing inflammation 
3. Chronic inflammation/ hepatitis 
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5.5 Data management and analysis 
The record of final outcome for the rats in the model development group 
was reported according to the final event and, or, contributory features to 
that event. For the final pilot study group, since the sample size was 
small, chi square tests with Yates corrections were used to decide on 
significance of the results. Comparisons on the liver functions between 
different groups of rats were analysed by means of Kruskal-Wallis test. 
Subsequent multiple pairwise comparisons were carried out with Mann-
Whitney's test on the data of blood results and on the volume of the right 
lobe, with adjustments to the p-values obtained using Bonferroni's 
correction methods. 
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5.6 Ethical considerations 
Approval was granted by the Department of Health of Hong Kong on the 
use of rats for the animal experimentations in this research. (Please refer 
to Appendix 2; Section 10.2 for further information on the details of the 
licences issued by the Department of Health.) All the experimentations on 
rats were conducted in accordance with the Animals (Control of 
Experiments) Ordinance, Chapter 340, of the laws of Hong Kong, the 
Special Administrative Region of China. 
The ethics issues related to the use of rats in this animal research was 
considered and approved by Professor Christopher J Haines ^  of the 
Animal Research Ethics Committee (AREC) of the Chinese University of 
Hong Kong. {Reference No. 01/013/MIS) (Please refer to Appendix 1; 
Section 10.1 for the copy of the approval letter issued by the committee 
on this research.) 
I myself was responsible for conducting this research and had been 
granted the following licences from the Department of Health, Hong 
Kong SAR, China, before the experiment commenced, they were the 
"Licence to Conduct Experiments (Form 2)", the "Endorsement to 
Authorize Experiments to Attain Manual Skill (Form 3)，，and the 
"Endorsement to Authorize Experiments without Anaesthetics or without 
Destroying the Animal (Form 5)". Yearly reports on the use of rats for 
1 Professor Christopher J Haines, the Chairman of the Animal Research Ethics Committee of 
The Chinese University of Hong Kong. 
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this research were sent for Dr. T.K. Au^ of the Department of Health. I 
had attended and completed several short-term courses launched by the 
Improving Postgraduate Learning Induction Programme of the Graduate 
School of the Chinese University of Hong Kong, including "Course on 
Animal Handling" (1998-1999)，"Course on Biological Safety" (1998-
1999)，“Course on Research Ethics" (1999-2000) and “Course on 
Intellectual Property" (1999-2000) 
The following precautions were always observed throughout this 
research. First, anaesthesia was induced to the rat before operation. 
Second, at least five-minute lapse was allowed for the anaesthetic drug to 
take action before operation, in order to ensure that all rats had undergone 
deep anaesthesia. Third, during the operation, close monitoring on the 
breathing pattern, flow of urine, and the frequency of body movement of 
the rats were noted. In case the rats showed signs of recovery from the 
anaesthesia, further doses of the mixture of xylazine and ketamine were 
given, not exceeding the upper limit of the rat's tolerable dose. Fourth, all 
rats were euthanaised with injecting of an overdose of about 150mg per 
kg of the mixture of xylazine and ketamine intraperitoneally. All the 
remains of the rats were disposed inside red plastic bags used especially 
2 Dr. T.K. AU is a Community Physician (NTE) of the Department of Health of Hong Kong. 
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for the handling of biological waste products and were stored in a low-
temperature room at the laboratory before disposal. 
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5.7 Participations of persons in the research 
I myself, the primary investigator of the research, was responsible for 
conducting all the experimentations on the rats, they included; dissection 
and catherization of the gastroduodenal artery, infusion of lipiodol-
ethanol mixture, blood taking and certifying the blood of the rats, all the 
measurements and data collection of the research, all the radiographic 
examinations of the rats, all the morphological investigations and all the 
photographs of the research. 
Mr. YIP Hei-yin Johnson, a research assistance of the Department of 
Surgery of the Chinese University of Hong Kong, who works at the Lee 
Hysan Clinical Research Laboratory, was responsible for the booking of 
Wister rats from the Animal House of the Chinese University of Hong 
Kong, the induction of Wister rats with liver cirrhosis and the caring, 
incubation and feeding of the rats for fourteen days after the LEM 
treatment. 
Dr. LIEW Choog-tsek, a pathologist and an associate professor of the 
Department of Anatomical and Cellular Pathology of the Chinese 
University of Hong Kong, was responsible for the histological 




Figure 5 Microscopic view showing gastroduodenal 
artery being isolated after tissue dissection 
^ ^ ^ ^ A silk loop at the origin of gastroduodenal artery ^ ^ ^ B 
• • 
A double loop • 
just to • 
bifurcation • 
gastroduodenal artery • 
Figure 6 Placement of silk thread loops around the 
gastroduodenal artery 
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Figure 7 Incision at the anterior wall of gastroduodenal artery 
• 
^ ^ ^ T i p ^ 1-F SLT was inserted into the dissected GDA ^ ^ H 
Figure 8 Insertion of a 1 -F silastic tubing (SLT) into the 
dissected gastroduodenal artery (GDA) 
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^ ^ ^ H Knots for fixing the silastic tubing in position 
• 
Figure 9 Fixing of silastic tubing within the gastroduodenal 
artery 
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_ . . • 
Figure 10 Simplified diagram showing how the GDA was ligated 
h H I ^ ^ ^ H H B I ^ H H 
^ ^ y s m W M i l i J i M M ^ ^ ^ B i i i U i i W i M B B I I D H i l 
direction of T ' ^ ^ T ^ ' T T l i y j / T f ' J H ^ ^ B B B i M l 
/ / Incision at 
‘ gastrodugcjerja 丨舰ry 
Figure 11 Simplified diagram showing the incision at the 
gastroduodenal artery 
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,Diagram showing the fixation of the siljastic. tubing 
' ^ , p m i i i l i p i i i l j 
Figure 12 Simplified diagram showing the fixation of the silastic 
tubing 
、颗袖r瘦m showing the direction of flow of LEM 
4|\ f f 顯，零• 





6.1 Problems and fate of rats in the model development group 
6.1.1 Experimentation on the model development group (50 rats) 
No. of rats Experiment involved/ Techniques adopted/ 
involved Purposes Difficulties encountered 
a. Dissection on the Some rats had abundant abdominal 
rats. adipose tissue in the abdomen that 
needed to be removed first in order to 
provide clear assess to the vessels. 
b. Retraction & Cirrhotic rats were relatively smaller 
identification of the in size, also their blood vessels, 
gastroduodenal Washing these vessels with 40°C 
artery (GDA). warm water helped to dilate them. 
c. Incision on the Gastroduodenal artery will easily be 
anterior wall of the ruptured during the incision made by 
5 normal GDA by utilizing a the microscissors, if the wound is too 
rats pair of large. microscissors. 4 normal rats and 7 cirrhotic rats died 
of serious bleeding of the hepatic 
artery during the dissection of 10 gastroduodenal artery, cirrhotic 
rats d. Catheterization of Comparing the hepatic artery and 
the 1-F silastic portal vein, the diameter of hepatic 
tubing with artery was one-half to one-third the 
modified tip. size of the vein. The artery was more 
elastic and pulsatile than the vein. 
Hepatic artery located deeper than the 
vein. These made catheterization 
difficult. 
During the procedure, 1 normal rat and 
5 cirrhotic rats died of serious 
bleeding of the hepatic artery during 
the catheterization of the IF tubing. 
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No. of Experiment involved/ Techniques adopted/ 
rats Purposes Difficulties encountered 
involved 
e. Uses of different silk Since the blood vessels of rats are 
ties on controlling the small, some soft and thin silk 
directional flow of threads were employed for 
lipiodol-ethanol ligation. Such fine thread easily 
mixture (LEM) lost tension. 
within the GDA. 
f. Uses of silk threads Silk ties easily slipped off the 
5 normal on temporally vessel that was ligated, especially 
rats ligation on the blood when it lubricated by blood. This 
vessels of the other was minimized by drying the 
& liver lobes. blood vessel with cotton packing-
gauze. 
10 
cirrhotic g. Practising (iii) & (iv). Temporary ligation was done by 
rats applying tension on the end of silk 
ties with the closed artery forceps. 
h. Drop by drop Although the small droplets of 
infusion of LEM into LEM could be seen within the 
the GDA. semi-transparency GDA moving 
slowly towards the proper hepatic 
artery, infusion of LEM was made 
under direct microscopic 
observation over the GDA that 
facilitated visualization. 
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No. of rats Experiment involved/ Techniques adopted/ 
involved Purposes Difficulties encountered 
i. Practising from (I) 1. The decrease of the body mass 
to (vi) again. and the diminution of the blood 
Refining the vessels increased the difficulty 
techniques on on the catheterization of the 
transcatheter GDA. 
intraarterial 2. The lobular changes on the embolization of . . . , DA cirrhotic livers increased the 
• difficulty on searching the blood 
vessels, increasing the amount of 
time required to complete the 
procedure. 
j. Finding the The range of dose of LEM infused 
maximum in normal rats was between 0.09ml 
tolerable dose of to 0.17ml. cirrhotic lEM on the 
rats cirrhotic Wistar Two given greater volume died. 
rats. 
The range of dose of LEM infused 
in cirrhotic rats was between 
0.08ml to 0.13ml. 
Five of cirrhotic rats given greater 
volume died, the maximum 
tolerable dose of LEM on the 
cirrhotic rats was 0.13ml. 
k. Setting up a The optimal exposure factors for a 
suitable exposure 300g of rats were 50kV and lOmAs. 
factors for the rats (HR mammographic films were 
with different used) 




6.1.2 Fate of rats in the model development group 
a. 4 normal rats and 7 cirrhotic rats died of serious bleeding of the 
hepatic artery during the dissection of gastroduodenal artery. 
b. 1 normal rat and 5 cirrhotic rats died of serious bleeding of the 
hepatic artery during the catheterization of the IF tubing. 
c. 3 cirrhotic rats died of anaesthetic drugs during the general 
anaesthesia. 
d. 2 normal rats and 5 cirrhotic rats died of the over administersion 
of LEM. 
e. 1 normal rat and 5 cirrhotic rats died of serious internal bleeding 
within 2-7 days post-LEM administration. 
f. 1 normal rat and 10 cirrhotic rats were euthanased upon finishing 
the experimentation (catheterization, etc) successfully on day 0. 
g. 1 normal rat and 5 cirrhotic rats were euthanased upon finishing 
the experimentation (LEM treatment) successfully on day 14. 
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6.2 Morbidity and mortality after LEM administration 
Twelve rats received the LEM treatment. All procedures of the LEM 
treatment on the twelve rats were uneventful and successful. The rats 
tolerated well with the treatment. No sign of illness or complications 
happened on the post-LEM treated rats over the period of fourteen days 
after the LEM treatment. 
38 
6.3 Results of radiological findings 
Radiography of the twelve rats on day 0 after LEM treatment showed 
lipiodol-ethanol mixture outlining the hepatic vasculature of the right 
lobe, with a peripheral and even distribution at terminal vessels outlining 
the liver margin, without involvement of the main trunk of the right lobe 
artery or the other lobes (Figure 15-22). 
Based on the radiographs taken before and after the LEM administration, 
there was no evidence of lipiodol accumulation detected in the lung in all 
the twelve rats (Figure 23, 24). 
Retention of lipiodol-ethanol mixture within the vasculature and 
persistence of the initial lipiodol-ethanol mixture distribution pattern was 
observed on the day 14 radiographs of all the rats. The right lobe of liver 
was clearly opacified by the LEM with a distinct boundary in both 
postero-anterior view and lateral view of the radiographs of all the twelve 
rats (Figure 15-22). The average volumes, the average change in volume, 
and the percentage volume reduction of the embolized right lobes of all 
the twelve rats in both groups as calculated from the radiographic 
measurements were shown in table 2 and table 5. There was a definite 
reduction in volume of the embolized lobe in all rats 14 days after LEM 
treatment, and there was no statistically significant difference in the 
absolute volume change between the two groups of rats as shown by 
Mann-Whitney test (p 二 0.59). There was also no statistical difference in 
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percentage volume reduction between the two groups as shown by Mann-
Whitney test (p = 0.94). 
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Measurement(M) on Day O Measurement(M) on Day 14 cu 
2 m "m ^ m M2 ^ 
0 
1 APD 13.20 13.30 13.20 8.50 8.50 8.50 
~ T D 3030 3K00 30.50 18.50 18.50 18.50 ~T Oo Oo Oo 6J1 610 ^ 
1 APD 11.21 11.20 11.20 10.60 10.70 10.50 
/ - - s ^ 
~ T D 33：00 33：00 33：00 25.20 B l O 25：20 P 
® ~ T 9：60 9 M ^ ^ O o W) 
名 ^ APD 13.40 13.40 13.50 10.70 10.70 10.70 
三 ~ T D 3X80 3 O 0 37.60 24.90 25.00 24.80 Ph T iTOO lliOO 13.00 T M T M T M fi ^ 4 APD 14.00 14.00 14.00 10.50 10.50 10.50 
~ T D 3 O 0 3 O 0 3 O 0 26.00 26.10 25.90 
C^ T I T M n i O 12I7O 0 6 0 6 0 6 Jm 
7 3 C APD 14.80 14.80 14.80 10.10 10.10 10.10 S 5 
j；；^ TD 3 0 0 26.30 26.30 26.30 
o ^ f 1400 14.00 9.04 9.04 9.04 
6 APD 20.60 20.50 20.70 14.81 14.81 14.81 
TD 4430 4 4 ^ 0 44710 27.00 27.00 27.00 
~T iXSO OlO 13：80 12：0 12：0 
y APD 18.07 18.07 18.07 8.80 8.80 8.80 
~TD MlO 23：50 BT^S 25^  25l0 25.10 
T i Z W 14：^ 7：06 i M 
^ ^ APD 18.10 18.20 18.00 11.80 11.80 11.80 
Sa TD ra 2440 ^ 
o 
^ T 1330 13：50 I3l0 OS 8.06 8.10 
O p APD 21.10 21.10 21.10 12.00 12.00 12.00 
~ T D 28：^  18：^  28：40 30：^  30：^  20.60 
rt f I 4 l 0 ITSO ^ ^ ^ tS ^ 2 Q APD 19.10 19.20 19.00 11.50 H.SO 11.50 
芯 ~TD JToo aToo JTM 33.00 33.00 33.00 
rt 
；M ~ ~ T 15；20 153O 9.09 9.09 9.09 a _ _ _ — — — — ^ ― — ^ ^ ^ ― 
1 1 A P D 20.06 20.05 20.07 12.00 12.10 11.90 
~ T D f f M 28^00 27180 36.70 36.60 36.80 
2 ~T 16：10 ^ ^ ^ 
1 2 APD 25.00 25.00 15.00 14.08 14.10 14.06 
TD 42i00 42IOO 38.60 38.60 28.60 f 14；0 lilOO iToO 10.08 10.08 >0.08 
Table 1 Data on the three dimensions of the LEM opacification 
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Rats type 
Normal rats Cirrhotic rates 
Initial liver volume Valid N 6 ~ 
(mm3) Mean 6710.33 9051.67 
Std Deviation 3340.87 2915.75 
Median 6056.00 8370.00 
Percentile 25 4132.50 7422.50 
Percentile 75 9030.00 10305.00 
Minimum 3300.00 6200.00 
Maximum 12600.00 14700.00 
Liver volume after treatment Valid N 6 6 
(mm^) Mean 2359.67 3406.17 
Std Deviation 1408.00 1473.39 
Median 2210.00 3341.00 
Percentile 25 1161.00 2122.50 
Percentile 75 3262.50 4533.75 
Minimum 960.00 1560.00 
Maximum 4800.00 5760.00 
Change in liver volume (after - Valid N 6 6 
before) (mm^) Mean -4350.67 -5645.50 
Std Deviation 2862.16 3390.29 
Median -3631.00 -4909.50 
Percentile 25 -5711.50 -7981.50 
Percentile 75 -2680.00 -2950.00 
Minimum -9880.00 -11658.00 
Maximum -1600.00 -2560.00 
Table 2 Data on the average volume and average change in volume of 
the right lobe of liver 
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Results of Mann-Whitney test 
Ranks 
Mean Sum of 
GROUP N Rank Ranks 
LV一DIFFNormal rats ~ ~ 43.00 
Cirrhotic rates 6 5.83 35.00 
Total 12 




Mann-Whitney U 14.000 
Wilcoxon W 35.000 
Z -.641 
Asymp. Sig. (2-tailed) .522 
Exact Siq. [2*(1-tailed Sig.)1 -589^ 
a. Not corrected for ties. 
b. Grouping Variable: GROUP 




% reduction in liver Valid N 6 6 
volume Mean 63.44 59.42 
Std Deviation 16.91 20.61 
Median 68.37 59.94 
Percentile 25 46.05 39.68 
Percentile 75 78.28 79.79 
Minimum 38.77 34.84 
Maximum 78.41 81.24 
Table 5 Percentage reduction in liver volume of the embolized lobe 
45 
90i 




3 60' O > 
u . � 
= 5 0 
• aaM 
c o 
O 40' _ _ L _ 
？ 
^ 30j 
N= 6 6 
Normal Cirrhotic 
GROUP 
Figure 14 Comparison on the % reduction in volume of the embolized 
lobe 
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Test Statistics b 
PCHANGE 
Mann-Whitney U 17.000 
Wilcoxon W 38.000 
Z -.160 
Asymp. Sig. (2-tailed) .873 
Exact Sig.[2*(1-tailed 9 3 / 
a. Not corrected for ties. 
b. Grouping Variable: GROUP 
Table 6 Test statistics on the volume changes of the 
embolized lobe 
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6.4 Results of liver function tests 
The findings of liver function tests in terms of the average reading of each 
of the test items before LEM treatment and 14 days after LEM were 
shown in table 7. Subsequent multiple paired comparisons between the 
subgroups were carried out by Mann-Whitney's test with adjustments to 
the p-values obtained using Bonferroni's correction methods. The p-
values of paired subgroup comparison for individual items of liver 
function tests were shown in table 8. There was significant difference in 
albumin and ALT level before and 14 days after LEM treatment in the 
normal group. There was significant difference in ALT level between 
day 14 and day 0 after LEM treatment in the normal group, and also 
before and just after LEM treatment in the cirrhotic group. There was 
significant difference in bilirubin, ALP, ALT when the cirrhotic group 
was compared to the normal group before treatment. There was no 
difference in any items when the cirrhotic group was compared to the 
normal group on day 0 and on day 14 after LEM treatment. There was 
significant difference in only ALP between the cirrhotic group 14 days 
after treatment and the normal group before treatment. 
Before the treatment with LEM, there was a difference in serum bilirubin, 
ALP and ALT between the two groups (p=0.009, 0.020 & 0.020 
respectively), indicating that the blood test was sensitive enough to 
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differentiate the liver function status between the normal rats and 
cirrhotic rats. On Day 14, there was no difference in serum albumin, 
bilirubin, ALP and ALT, indicating that LEM might be equally tolerated 
by both normal rats and cirrhotic rats when lobar ablation was limited to 
the right lobe of liver. 
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Normal Normal Normal Cirrhotic Cirrhotic Cirrhotic 
Rat Rat Rat Rat Rat Rat 
No Treatment Treatment No Treatment Treatment 
Treatment (day 0) (day 14) Treatment (day 0) (day 14) 
^ ^ B V a l i d N 6 6 6 6 6 ^ 
Mean 15.13 10.60 11.78 13.10 10.82 11.80 
Std deviation 1.28 2.30 1.72 0.56 1.89 1.48 
Median 15.55 11.00 12.00 13.20 11.00 12.00 
Percentile 25 14.40 9.25 10.75 12.70 9.00 11.00 
Percentile 75 16.10 12.25 13.25 13.70 11.00 13.00 
Minimun 12.90 7.00 9.00 12.20 8.00 9.00 
Maximun 16.30 13.00 14.00 13.80 14.00 14.00 
B I L Valid N 6 6 6 6 6 6 
Median <1 2.00 2.00 2.00 0.50 0.75 
Percentile 25 <1 <1 0.88 2.00 <1 <1 
Percentile 75 <1 3.00 2.00 3.00 2.00 3.00 
Minimun <1 <1 <1 謹 <1 <1 
Maximun <1 6.00 2.00 3.00 3.00 4.00 
A L P Valid N 6 6 6 6 6 6 
Mean 149.00 200.80 214.67 243.29 243.27 248.10 
Std deviation 39.92 54.18 100.27 46.37 90.50 44.30 
Median 144.50 229.00 199.00 230.00 222.00 234.00 
Percentile 25 112.00 160.00 175.50 210.00 169.00 222.00 
Percentile 75 179.00 238.75 206.25 276.00 331.00 270.00 
Minimun 111.00 118.00 116.00 196.00 118.00 196.00 
Maximun 203.00 247.00 469.00 332.00 407.00 329.00 
Valid N 6 6 6 6 6 6 
Median 52.50 83.00 11.00 104.00 U.OO 83.00 
Percentile 25 50.00 52.00 1.00 93.00 1.00 44.00 
Percentile 75 69.00 538.50 20.50 111.00 67.00 109.00 
Minimun 46.00 19.00 <10 83.00 <10 <1 
Maximun 91.00 1782.00 48.00 121.00 114.00 209.00 
Table 7 Results of liver function tests 
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Comparison of Subgroups ALB BIL ALP ALT 
Normal group ve rsusNorma l group 0 . 0 9 0 1 . 0 0 0 1 . 0 0 0 1 . 0 0 0 
pre-treatment post-treatment (day 0) 
Normal group versus Normal group -0 ,030 0 .120 0 .660 0 .0101 
pre-treatment post-treatment (day14) … ^ ^ ^ ^ 
i S i )編 
Normal group versus Normal group 1 . 0 0 0 1 . 0 0 0 1 . 0 0 0 
post-treatment (day 0) post-treatment (day 14) 
Cirrhotic group versusCirrhot ic group 0.2700.1501.000 
pre-treatment post-treatment (day 0) 
Cirrhotic group ^^i^iuiCirrhotic group 0.3301.0001.000 1.000 
pre-treatment post-treatment (day 14) 
Cirrhotic group versusCirrhot ic group 1 . 0 0 0 1 . 0 0 0 1 . 0 0 0 0 . 6 1 0 
post-treatment (day 0) post-treatment (day 14) 
Normal group ^^iiiliiCirrhotic group 0.140 0.020 
pre-treatment pre-treatment ^ ^ ^ 
Normal group versusCi r rhot ic group 1 .000 1.000 1.000 0 .380 
post-treatment (day 0) post-treatment (day 0) 
Normal group versusCi r rhot ic group 1 . 0 0 0 1 . 0 0 0 0 . 1 7 0 0 . 0 6 0 
post-treatment (day 14) post-treatment (day 14) 
Normal group versusCirrhot ic group tf.Ol® 1.000 & 1 . 0 0 0 
pre-treatment post-treatment (day 14) ^ ^ ^ ^ ^ 
Table 8 P-values of paired subgroup comparison for individual 
test items 
P-value < 0.05 indicates it is statistically significant, (in grey box) 
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6.5 Results of liver morphology 
Immediately following the completion of infusion of lipiodol-ethanol 
mixture, the original reddish brown colour of the liver tissue of the 
embolized lobe immediately darkened in all the twelve rats of the final 
pilot study group. 
Gross examination of the liver specimen on day 14 after LEM treatment 
revealed significant shrinkage of the right lobe with pale yellowish 
discolouration and a smooth surface in all the twelve rats (Figure 26, 
Figure 28). The embolized right lobe became more spherical in shape, 
although the changes in shape of the embolized lobe of the cirrhotic rats 
were less obvious than those of normal rats. The appearance of the other 
liver lobes was unchanged as compared to the pre-treatment status. 
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6.6 Histological results 
A single pathologist, Dr. LIEW Choong-tsek, conducted histological 
examination of all specimens�. This eliminated inter-observer variability. 
The pathologist was kept blinded to the category of the specimens that he 
was investigating. Thus, bias on the investigations could be kept to the 
minimum. Histological examination of all the specimens of embolized 
right lobes of both normal and cirrhotic rats revealed that complete non-
inflammatory true vascular infarction had occurred in the right lobes. 
There are six histological features for true vascular non-inflammation 
infarction. First, liver cells with indistinct cell borders. Second, liver cells 
with indistinct nuclei. Third, loss of cellular architecture. Fourth, absence 
of inflammation in early infarction. Fifth, coagulative change. Sixth, clear 
zone of demarcation between viable and necrotic tissue. In the present 
study, all these features were present in the embolized right liver lobes of 
all the twelve rats. 
3 Dr. CT LIEW is an associate professor of the Department of Anatomical and Cellular Pathology 
of the Chinese University of Hong Kong. . 
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6.6.1 Histological analysis on normal rats 
For normal liver tissue, all hepatocytes (H) had distinct cell borders and 
the cell nuclei (N) were clearly seen (Figure 29，30). However, 14 days 
post-LEM treatment, the cell border of all the hepatocytes became 
indistinct, with loss of architecture within the liver cells. These features 
are those of true-vascular infarction (I) of liver tissue, as shown on figure 
31，figure 32 and figure 33. (Please refers to page 53; section 6.6, on the 
characterises of cells that underwent true-vascular infarction.) 
6.6.2 Histological analysis on cirrhotic rats 
Histology confirmed the specimen of liver cirrhosis as indicated by the 
large amount of connective tissue surrounding the hepatocytes (Figure 
36). Histological study with high power microscopy showed that necrosis 
(N) and coagulative changes occurred in the liver tissue. Loss of 
architecture was seen in all the hepatocytes. Cell nuclei and cell borders 
of these liver cells were indistinct. A clear zone of demarcation between 
viable cells and necrotic cells was seen. All these findings were those of 
true-vascular non-inflammatory infarction of the liver cells (Figure 36). 
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Rat Anaesthetic Protocol (IP Route) 
Body weight of xylazine Ketamine 
Rat (gram) (20 mg/ml) (100 mg/ml) 
10€ 0 0 8 
TM 0.04 a i 2 
200 0?16 
2 M 




S ^ 0.13 0.40 
Remarks: xylazine dose: 5 mg/kg 
Ketamine dose: 80 mg/kg 
Table 9 Protocol on the use of anaesthetic drugs 
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Figure 15 Radiograph (PA view) of a normal rat on day 0 showing 
LEM retention in the right lobe 
Figure 18 Radiograph (lateral view) of the same rat on day 14 
showing LEM retention in the right lobe 
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Figure 17 Radiograph (lateral view) of a normal rat on day 0 
showing LEM retention in the right lobe 
Figure 18 Radiograph (lateral view) of the same rat on day 14 
showing LEM retention in the right lobe 
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Figure 19 Radiograph (PA view) of a cirrhotic rat on day 0 
showing LEM retention in the right lobe 
Figure 18 Radiograph (lateral view) of the same rat on day 14 
showing LEM retention in the right lobe 
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Figure 21 Radiograph (lateral view) of a cirrhotic rat on day 0 
showing LEM retention in the right lobe 
Figure 18 Radiograph (lateral view) of the same rat on day 14 
showing LEM retention in the right lobe 
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Figure 23 Radiograph (PA view) of a rat before LEM treatment 
H I 
Figure 24 Radiograph (PA view) of the same rat after LEM 
treatment showing that no lipiodol was seen on the 
lung 
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C: Caudate lobe 
M： 
^ ^ ^ ^ ^ P * � ’ ? � L: Left lobe 
R: Right lobe 
Figure 25 Morphology of liver lobes of normal rats 
C: Caudate lobe 
^ ^ ^ ^ K ^ ^ B g l F - M: Middle lobe 
- L: Left lobe 
, R : Right lobe 
Figure 26 Morphology of liver lobes of normal rats 14 days after 
LEM 
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Figure 29 Histology of normal liver tissue of rats (x100) 
H | 
Figure 30 Histology of normal liver tissue of rats (x400) 
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Figure 31 Histology of the embolized liver lobe of a normal rat 14 days 
after LEM (x100) 
Necrosis (N) and atrophy (A) were seen in the liver tissue 
64 
• 
Figure 32 Histology of the embolized liver lobe of a normal rat 14 days after 
LEM in the majority of liver cells shown in this view (x400) 
True-vascular infarction (I) occurred. 
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Figure 35 Histology of the liver lobe of a cirrhotic rat without LEM 
treatment (x200). No true-vascular infarction was observed 
_ 
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Figure 36 Histology of the embolized liver lobe of a cirrhotic rat 
14 days after LEM (x400). 
True-vascular infarction occurred over all the 
hepatocytes 
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Caption for figure 33: 
Histology of the embolized liver lobe of a normal rat 14 days after LEM 
treatment. True-vascular infarction (I) occurred in all the liver cells 
shown in this view. The cell nuclei of those hepatocytes which had 
undergone true-vascular infarction. Viable hepatocytes with distinct 
nuclei located on the right hand side indicated a clear zone of 
demarcation. 
Caption for figure 34: 
Histology of the embolized liver lobe of a cirrhotic rat 14 days after LEM 
treatment. True-vascular infarction (I) occurred in all the liver tissues. 
Unusually large amount of fibrous tissue (F) was seen surrounding the 
hepatocytes indicating the presences of liver cirrhosis. 
Caption for figure 35: 
Histology of the liver lobe of a cirrhotic rat without LEM treatment. The 
presence of mature fibrous tissue surrounding hepatocytes confirmed 
successful induction of liver cirrhosis. Cell nuclei and cell borders of 
hepatocytes were distinct, showing that true-vascular infarction had not 
occurred before LEM treatment. 
Caption for figure 36: 
Histology of the embolized liver lobe of a cirrhotic rat 14 days after 
LEM. Necrosis and coagulative changes occurred in the liver tissue with 
loss of architecture noted in all the hepatocytes. The cell nuclei and cell 
borders of these liver cells were indistinct. These histological features 
were characteristics of non-inflammatory true-vascular infarction. 
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7 Discussion 
7.1 Problems encountered in the development group 
During the development of this animal model, the following problems 
encountered: 
a. Cirrhotic livers were different in architectures as compared with the 
normal livers. Besides, cirrhotic livers of different stages will have 
differences on their architectures as well as the shapes. As a result, 
these would increase the difficulties in identifying and 
catheterizing the gastroduodenal artery (GDA) of the cirrhotic 
livers. 
b. Vessels of the cirrhotic livers were relatively smaller in diameter 
than those of the normal livers of the same age. Also, cirrhotic 
livers had undergone fibrotic changes within the whole organ, 
resulting in an increased intrahepatic pressure; this impeded the 
passive delivery of LEM by the blood flow within the common 
hepatic artery. Any application of pressure while infusing the LEM 
into the liver lobe would result in an over-infusion of the mixture. 
This necessitated greater care and patience in order to ensure the 
complete embolization of the lobe of the cirrhotic liver. 
c. Some GDAs of the cirrhotic livers were so small in diameter that 
despite of their elasticity, 1-F silastic tubing could not be 
introduced into them. 
d. One challenging step of this study was making an incision on the 
anterior wall of the GDA without rupturing it. The incision should 
be large enough for the entrance of a 1-F silastic tubing. Also, the 
use of silk threads on diverting the flow of blood into the proper 
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hepatic artery without causing a leakage of lipiodol-ethanol 
mixture to the other parts of livers was technically demanding. For 
anyone attempting to use this model, it would be necessary to 
acquire the skill by practising the techniques on some normal livers 
with larger blood vessels first. Practising the techniques directly in 
rats with liver cirrhosis would be best reserved for those who have 
acquired excellent technical skills. 
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7.2 The pilot study group 
7.2.1 Bio-distribution property of lipiodol relevant to clinical 
application 
The clinical use of lipiodol has been well published (9, 10，11, 12). A 
number of lipiodol-based diagnostic and therapeutic procedures have 
been devised. Following intra-arterial administration, lipiodol is 
selectively retained within hypervascular liver tumors while it is cleared 
away by the normal part of the liver (9). Such bio-distribution property is 
the basis for a lipiodol based embolization or chemoembolization 
procedures developed as a therapeutic modality for liver tumors in 1980 
(10，11’ 12), in which lipiodol was used for producing a temporary 
embolic effect, as well as a vehicle for drug delivery. However, 
intratumoral retention of lipiodol was not permanent (9)，even with 
additional arterial occlusion using particulate agents, as was usually the 
case for lipiodol based chemoembolization procedures, lipiodol would 
st i l l be eventually drained away. This is due to the presence of peribiliary 
plexa which provide central arterio-portal shunting, even when the 
peripheral hepatic arteries and arterioles are embolized with gel foam 
powder (13). 
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7.2.2 The concept of hepatic segmented or lobar ablation 
The aim of hepatic segmental or lobar ablation as applied to tumor 
therapy is to create avascularity and therefore infarction of the liver tumor 
as well as the respective hepatic segment or lobe harboring it, thereby 
eradicating the tumor. Hepatic segmental or lobar ablation with 
transcatheter intraarterial embolization can be achieved if a potent 
embolizing or ablative agent, which is effective in causing complete 
avascularity, is identified. The use of ethanol as a thromboembolic agent 
for the liver has been studied in animals since 1984 (4’ 14). In these 
studies a number of crucial factors which had led to unfavorable 
outcomes were identified, including the use of undiluted absolute ethanol 
(4, 14)’ excessive injection pressure and high local concentration 
produced by wedging of the catheter (14)，lack of opacification and image 
control of ethanol injection and therefore backflow of ethanol (4), and 
non-selective arterial catheterization with ethanol injection at the main 
hepatic artery. The outcomes were the development of peribiliary fibrosis 
akin to sclerosing cholangitis (14)，acute pancreatitis (4), and vascular 
spasm and occlusion of the main hepatic artery, which preclude 
satisfactory flow of ethanol to the peripheral hepatic arterioles and led to 
formation and hypertrophy of collateral arteries (4). 
Absolute ethanol, when diluted with lipiodol provides fluoroscopic 
opacification that enables visualization of where the agent is being 
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distributed, and confirms that it is all embolising the target region and not 
leaking to other non-target areas. Furthermore, the lipiodol prevents rapid 
flushing out of the ethanol thereby prolonging and accentuating its 
endothelial effect. 
Administered intra-arterially using minimal necessary pressure and 
relying on normal arterial flow for delivery to the target and with highly 
selective catheterisation, overcomes the previously identified 
unfavourable factors and prevents the development of the undesirable 
outcomes of gastrointestinal or biliary tract complications and, results in a 
much more modest post-embolization syndrome (15). However, before 
such an agent can be used clinically, the possibility that there may be a 
difference in outcome in the cirrhotic liver has also to be taken into 
account. 
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7.3 The need for the present study 
The recognition of the peribiliary plexa as an important pre-sinusoidal 
pathway for shunting of iodized oil from the hepatic artery to the portal 
vein, by direct in vivo microscopic observation (2), has allowed us to 
understand the flow kinetics of hepatic microcirculation in normal livers 
of small animals, and to account for the dual embolization effect of 
lipiodol-ethanol mixture in producing complete devascularization and 
infarction of the embolized liver lobes in normal livers of rats (3); 
however, the behaviour of a lipiodol-ethanol mixture in the 
microcirculation of cirrhotic livers, and particularly, the extent is it 
affected by the distorted intrahepatic architecture and modified 
intrahepatic shunting as a result of cirrhosis, remains unknown. As liver 
cirrhosis is a common predisposition of hepatocellular carcinoma (6), 
which in turn is one of the reasons for the development of lipiodol-
ethanol mixture therapy, this study was aimed to make an initial step in 
search of the answer. 
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7.4 LEM in cirrhotic rat compared with the normal liver rat 
In this pilot study, the parameters selected for comparing the 
effectiveness of lipiodol-ethanol mixture embolization in the cirrhotic and 
normal groups were the intrahepatic distribution pattern of lipiodol-
ethanol mixture and evidence of lipiodol accumulation in the lung as 
depicted on radiography, the relative volume change of the embolized 
lobes on radiography, the appearance of the embolized lobes on gross 
examination of liver specimen, and the histological finding of degree and 
extent of infarction. In this small study, there was no difference between 
the two groups for any of these parameters, indicating that a larger study 
is required to determine whether there is some difference, and its 
magnitude. 
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7.5 Liver function markers in cirrhotic liver 
Serum albumin is a plasma protein produced by liver tissues. It is a very 
important factor in regulating the exchange of water between plasma and 
interstitial space (16). A drop in the concentration of serum albumin 
represents a failure of liver tissue to produce adequate amounts of 
albumin for normal physiological demands. The cause of reduction in 
albumin concentration in rats in this study could be firstly, drug-induced 
liver cirrhosis and secondly, the ablative effect of LEM causing a 
permanent damage in the liver tissues of the embolized liver lobe. 
Therefore, one would expect the albumin to be lower in cirrhotic subjects 
and fall with any hepatocellular damage. 
Bilirubin is a bile pigment produced as a by-product during the 
breakdown of haemoglobin and reduction of biliverdin. It normally 
circulates in plasma and is taken up by liver cells and conjugated to form 
a water-soluble pigment before excretion in the bile and hence into the 
gut to be removed from the body mainly in the faeces (16). A 
compromised liver function would result in accommodation of serum 
bilirubin. Therefore, one would expect this to be raised in cirrhosis and to 
rise even further with increased damage to the liver. 
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Alkaline phosphatase is an enzyme localized on cell membranes that 
hydrolyses phosphate esters and liberates inorganic phosphate, the highest 
concentrations are found in the liver, biliary tract epithelium, and bone. 
This enzyme test is important for detecting liver disorders. Within the 
liver, ALP is present in Kupffer's cells. Serum enzyme levels of ALP are 
greatly increased in both extrahepatic and intrahepatic obstructive biliary 
disease and cirrhosis (16，17). 
Alanine aminotransferase (ALT) is an enzyme found predominantly in 
the liver (16). Injury or disease affecting the liver parenchyma will cause 
a release of this hepatocellular enzyme into the bloodstream, thus 
elevating serum ALT levels. Therefore this enzyme is not only sensitive 
but also quite specific for hepatocellular disease (17). One would expect 
the serum levels to be raised from any cause of hepatocellular damage. 
One might expect that the changes of the blood tests would follow the 
following patterns: In the normal rats serum albumin should fall after 
embolization and bilirubin, ALP and ALT rise. This was in fact the case. 
In the cirrhotic rats prior to embolization, one would expect that albumin 
should be lower and bilirubin, ALP and ALT should be higher, than that 
in the normal rats, reflecting the fact that the liver is already undergoing 
damage. Again, this has been confirmed in this study. In the cirrhotic 
liver, further significant damage by embolization would result in further 
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deterioration of these parameters. Surprisingly this is not the case. Serum 
albumin remains relatively stable, the bilirubin, ALP and ALT actually 
improve slightly. However these are only the gross trends. Statistical 
analysis shows that there is no striking difference in most of these 
measured values in this small sample. 
The observation that the serum markers of hepatic health do not change 
significantly following embolization, and in fact appear to improve a 
little, seems contrast to the finding of some deteriorations in liver 
function tests in the normal rat which has undergone embolization. An 
explanation that may be offered is that the cirrhotic liver is already 
undergoing a hypertrophic stimulus, which is further, boosted by the 
sudden loss of one of its lobes, and this result in an increase in the 
number of healthy liver cells, whereas the normal liver is not undergoing 
such a stimulus until the damage occurs. Of support to this theory of 
active hypertrophy it is noted that the cirrhotic livers were much larger 
than the normal livers. This also indicates that they were at a relatively 
earlier stage of the cirrhotic process. 
When considering the application of this technique in the human with 
HCC, this must be considered as a possible limitation of the study. The 
findings of this study suggest that in the relatively early, cirrhotic rats 
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with reasonably functioning liver tolerates further damage very well. This 
may not be the case in a chronically cirrhotic and poorly functioning 
liver. However, the pilot study group is too small to establish the 
magnitude of the possible adverse effects so it must be emphasised that 
theses are suggestions and not conclusions. The only conclusion that can 
be drawn was that there were no serious adverse effects that would 
indicate that this model could not be used for future experiments. 
I 
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7.6 Discussion on the assumptions of the research 
1. In this research, some assumptions were made that might not be 
correct. It was assumed that all the twelve active and healthy 
looking Wistar rats had health livers. 
2. It was assumed that all the rats with drug-induced liver cirrhosis 
form the same severity of cirrhosis, based on the gross 
morphological appearance of the livers observed at the time of 
arterial catheterization. 
3. Lipiodol is cytotoxic in nature. Kan et al. (1993) estimated that a 
dosage of roughly 0.1 to 0.3mL/kg lipiodol was safe for injection in 
normal liver parenchyma. In this research, the maximum dose that 
had been used on cirrhotic Wistar rats was 0.13mL/kg, within the 
safety range for normal liver parenchyma. It was assumed that the 
safety range of 0.1 to 0.3mL/kg of lipiodol (18) was equally 
applicable to cirrhotic and normal Wistar rats. 
4. The volume of the right liver lobe was calculated based on the 
assumption that the shape of right liver lobe was similar to that of a 
prism. However, only the percentage change in volume of the right 
liver lobe was the focus of this research, the error so introduced was 
minimal, provided that the shape of the embolized lobe did not 
change too much. 
80 
5. The volume of the right liver lobe was calculated from 
measurements taken from the area opacified with LEM on 
radiographs. It was assumed that the infused LEM had infiltrated 
the whole of right lobe and only the right lobe, and that the LEM 
remained within the right lobe in the following fourteen days. These 
particular assumptions were supported at laparotomy by the extent 
of colour change, and confirmed to be only in the right lobe 
immediately after LEM injection, by the radiographs, and by 
examination of the liver specimens on day 14，which showed the 
extent of yellowish discolouration and volume change involving 
only the right lobe. 
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7.7 Assessment on measurement error 
As mentioned on page 18; section 5.2.5, adopting some calibration 
procedures on the measuring instruments reduced systematic error. 
Having said that, systematic error can never be eliminated completely 
because there is no perfect measuring tool in the world! 
The number of measurements was increased to reduce the imprecision or 
unreliability of measurements, and reduce the magnitude of the random 
component (imprecision or unreliability) of error. Nevertheless, 
increasing the number of measurement does not reduce the magnitude of 
the bias (19). This bias may be increased. 
In the current experiment, this may have caused some differences in 
volume estimation and may have underestimated the volumes in the 
cirrhotic infracted lobes because these were more globular than the 
previously normal then infected lobes. However, the percentage changes 
were likely to minimize this bias. 
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7.8 Errors in the pilot study 
Since the number of rats studied was small, any error in the measurement 
would affect the conclusion that was drawn out of the data obtained in 
this experiment. If there were any error in the measurement, it would 
further be magnified by the subgroup analysis of the data. Thus, the small 
sample size of this study is a limitation on the interpretation of the results, 
and the suggested explanations purely conjectural and needing a larger 
study to test whether such suggestions may be true. 
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8 Conclusions 
1. An animal model useful for studying the effect of transcatheter 
intraarterial embolization with lipiodol-ethanol mixture in cirrhotic 
livers was successfully established, and some of the problems 
associated with creating this model identified. 
2. The pilot study showed that the model was a feasible one for the 
purpose of studying LEM effects in cirrhotic livers. 
3. The pilot study suggested that 
a. Selective hepatic lobar ablation with intra-arterial administration 
of lipiodol-ethanol mixture can be achieved in both the normal 
liver and cirrhotic liver of rats. 
b. There is no significant embolization of the lung. 
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9 Future experiments that may be performed using 
this model 
a. A larger study to confirm that LEM administration in cirrhotic rats 
is indeed safe, preferably in a population of rats with longer 
established cirrhosis. 
b. To test whether the lipiodol-ethanol mixture should be in a 
different ratio for cirrhotic livers. 
c. To investigate the mechanism of how lipiodol-ethanol mixture 
works inside the cirrhotic livers. 
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10 Appendices 
10.1 Appendix 1: 
Copy on the letter of ethics approval from the Animal 
Research Ethics Committee of the Chinese University of Hong Kong 
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10.2 Appendix 2: 
Copy on the licences issued by the Department of Health of 
Hong Kong. 
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”. ........ . .. • . ,、 . • ：： : :i： - • : • 
F o i m 2 ; : Licence to Conduct Experiments ‘ 
.：‘..、:遇评".-/： :^灼：涵• "ii：：：；;^'!：!'^!；',‘-
Form 3 E n d o r s e m e n t to Authorke ^perimeats to Attain Manual Skill : 
Porm 5 ： Endorsement to Authorize Experiments without - < 
Anaesthetics or vsdthout Destrojdng the Animal 二 - •� ’ ’ ’ 
. , - ： ： - . . • ‘ ：•；• i'^ j^ '；：： - 二 ,•i-v.a：：：：.；,：：;-：：-：：；:.：势 
Your attention is drawn to the followng extracts ofjhea^ye OrcUnancc:- y ‘ _ 
“4. Every Licensee shall kkp up-to-date a book in the form set^ � ^ 
out as Form 6 in the,Schedule in which he shall record the particulars ' � ‘ 
therein indicated of experiments performed by him'.V,, ^ - • � : � 
5, Every Licensee shall render to the Director of Health on or : ‘ 
before the 1st day of Jamuoy each year a'return in the form set out as � ， , > 
Form 7 in the Schedule of all expcrimrats performed by him during 巧 - � • 广 、 . 
the preceding twelve months, or forW"period from the date . , 
coining into operation of these regulations to the following 1st day of ' ' ' ' . 
January, as the case may be." \ V ' � " ‘ � 
One copy of each Form 6"and 7 are apj^nded. ‘_:-；! >、，、<, ., . ... . : " i i „ . ： ： ‘ u ； : ' ' " • "liEiSffi,^；.-；'；^liiSP • :..•...‘•:： 
.... - " 、 . … . • - •• , .；：；：： . - - . . . : . 7 V . ” : : : : : - . . - : - . - : ; . . . . -
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--::-，-"巧二: 广 • .:�：.；； '：；;.： • h iS^ - lV " V ： •.:，.:.:. 
‘.-V〒：： ..?、“.:- .. • •••+.‘:'：.：，.,..:’.+‘ .： ；：-. >:.•:?“;:；：‘,“::!；；：^:—.-.心：.-:::...;.；； .^::;:;’5；^<:>>、:;:，"：-7:.:,::4} :^..,..:*::: •二：：一:•’-—::::“:三::;55:�'.mi;;i$:::i^ ;:vr::i:iM,/..:.:i ::,::、:： .. ：.:.：•:•.：： . •-
Pursuant to the Personal Data (Privacy) O r t o e , a statement of p ^ o s e ' r e g ^ d m g the 
collection of personal data relating to liceace/permit applications under the Ammals�(Control f 
Experiments) Ordinance is also attached for your information. 
‘ • . 广：！^二：.::‘:-:—...  . :；.； : : : : +』 ; : : '〜 ' : . : : ; . . . ,：： .： ' -；•： = ' ' -：. • ...、 
. 卜 . . ： ； - - ^ ' . ：.^  Ybursisincerely,：... 
� — 9 
： ‘ � 
> . (Dr. T. K. AU) ^ 
' ‘ Community Physician (NTE) 
Department of Health 
. . . . . . . . ：•-. • ••••.： ：• • ‘ . ：•• i；：.：； .…丄：• • 
、 . . < : — : . ^ •-'•：；•;•.-： 〒：：^—:•.....‘":：.:.::•::.:;..々 ..：.:;」，:ii:i、,义….::..::.、:、.::：.：：....,.:. 
ED£L � 一 
TKA/AK/ic �� “ ^ “ . 
-、.…....‘义:：足 ' G i t : :安•：.:口"^:。::搭厂 - S:'：..:；电嫂 . ; i i s i l / t f'/：; ；--"^：：'-':.V�.k:： 
… 二 》 矜 . 锅 i臂,;二;(jjp 一 ； ： 
；；-..：•.; .：：! ：：. „::.�. “.‘."：；. .trUrrS'二 •：-' . ：： - ；‘ ；；；：：.^  - ；；^ i •. ；,：'•••'：•；：•. 
. . ” - - : : • 贺 ^^  
…、.：-.“"，々-:“:： .:、:-.:"> •： . • - - ； ； ; ； ； ： V V ； ' ； ： 3 ； » ： ： ... UK- - v.- . .“- ： . • • - ：!.；. •. .-； .•.、.‘，- •： • • , .. .、•.-“,.….二‘ .. “.<j-,=vV'-： ” . 
.： . : . . . : 〈 . . . ’厂.‘ -j"-.；. • • •'• ,•!'•'•'： •• { ^  ‘“ ： ：.；. , •"A/xlv ；；；：{；*；?< •iV-i-r!^  -':：- .-.” - ••••；：；.• ^,；!';'•!：；：：'<,; •； 
：：.?-/^- •：：：!“：• • ： ； ^ ‘ ； ' - ^ ' ； ； ^ ： Iss；!：：：^ ^^  
• ,、：. . • • \ . 、！t: - .• • •. .： ： • ；；：.?：;-«•. ;v：； ；•!： • • .•；.. '•v.- -<(>!： = : ； .•>- •.'1.： . . 
..^：^：-.；^：:； •/:：=;、:、>；〉--..-“：.：… 
.... . . . . . . ： Mi； S,；‘；^；!：^；:；"；^：^：；?^ ^^ ；：:^  ： • -
… ：：....:.:::.;:.__::;‘:_ 
. • ，- “ ：.：• . ： ,.： ••:‘： ‘ x -v^-' r ： 、 ？ ; y ...... ^‘！-：；^^ i S i i V i；；-；：；..： 
. - •• .、.•.：••-,. .. • ..,:..‘：::,..‘：.. .:..:.. .. • - • 
........::.•..:.:...‘..•.•......：•... .-；_.,：•：.；；.;：：.•_：；. .'^“； ：：；；： :r.； ； ：；；.：；； ；：；.：;• ： ； J： ； 
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‘ Enrm2 - ‘ 
.",>.�.•；K.:丨::’.�丨:縫丨:i::，::.::辨^^ 丨:::i:�:f.�. ..:.:二�::::!�:!::::_ 
Name “： CHAN Tai-po _ ^ ^ 
Address ： Dcpartmcat of Diagnostic Mologj - k Oigaa W i n g . — 
：|!：；\- f’卜• . ：, �., ：'. ’-.i:r...-'.：：-..... •'.：；…….V. ”..::.’ H .. .::�.. ？'SS； 
一• . - ： “ 二 ” ‘ .V • •.-SxA ：. .«•；；•• .IS:J t.  riv；" •.：1'« .'：;•:;.. W-M ；.：： ； • ： '.••：：；：；'：.1 .：； • •  ：...； .... ： ；； ,;、.，,. !•：； = ••;- •. 
• :.••.、;,..". ”.-':•；;•:::,•?. , ？ ！;ff；；;：；：!.：：；； r ：‘ ：•. • ：•： ： 5：： 、..:::.|.“ ..^:;“;:‘.？;.:... •..��,.. r 
„ � ^ r ^ t i o n 7 of the Animals (Control of Experiments) Ordimmce. Chapwr 340. � . 
UK a b o v 二 二 二 - i L 卿 � r — n 胁 a t � , 一⑷ and upon : 
= 遍 0 一 - 一 “ , , … ： ‘ , , I 
•… ‘........— I. • ’ ‘ • ：.-^  
- — : : : . . : : — ;「 :無…‘ f • ) ^i'-spii-!；：；；；； .ft-；:fi;;;‘;:pii:�gi 
Type of experimented} . 寶 、 ： . 肩^^ 
. ..xr^rimcnt using wts. Lipid�丨-alcohol mixture >vm be injcctei…to the h印adc ： : 
A i u m a l expcnracm u s t n g ^ . . ^ 
Placc(s)>^cre.xpcnmcnt(s)a«y be conduc t ， ： 、 : 
UeHy邮Cl,m-cal:R;sca«hUbc^ra!�ry,7mginicaISd_mds”mi广,:,‘：:.？楚 
••• …|;:iV;.H^,’:j:.ij!a;，gv“-:-, v. .:: . ； ’ •. ...-.....‘ ... ,.'..::、 二 了 二 . : 二 , 
‘ “ ‘ I ‘“ ‘‘'I'll'''•"••"'•- ‘ '•‘ ‘ '• • ““：" . • ’ ..“:•.. - ；.?:。‘.、：• ：： 潘;"!：；;；；；！：‘-i iil-v:. 
Conditions 卞:.、 
(1) S如 h e x p e r i m _ > m a y o n l y > c « m d « ; t c d f o r t h e — w i n g p u r p o s c s L � … ’ �一 
To studv the clftct of the embolization of hepatic artery with Hpidol-alcohol on the function , , ^ crfUwliveton animals. ' , . ； ： ^；：^-^ 
(2> This liccnce is valid unUl. 31.12.2002…丨‘^ 丨， ； ; ； ] “ 
— ； . „：. . ： 
. “.；• ：^' -.. V--V；' 
： 議 ^^  
We are committed to proMtg qiuUUy cfieftt^emek 丄 ) 
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EcnnJ • • , 
(to be endorsed oa reverse of Form 2 or attached thereto) 
� Endorsement to Aulhonzc i -
— Experiments : < ^ " 
to Attain Manual Skill 、 ‘ 
• • .•：.；|：；-：：：-  "asi;;:-；：-： : ::;:.!、•:.:!,:; • •； -i；：：•;::v ；• ；；£ ：：•：.••：;：：：-； / r I：::广：r • 
Name ： CHANTai-po . 
Address : Department of Diagnostic Radiology & Organ Imaging, 
PWH , < ? … - ‘ 、 
Bv virtue of section 8 of the Animals {Control ot Experiments) Ordm^cc, Chapter 340 卜：. 
boiaer of this Licence is hereby authorised to perform the type of expenmeaKs) at the pto^s) � 
t 二 cct to thccondmons hereinafter mcntionedMbr the pu^se of 咖脚 g ,么 
manual skiU. . 
.,�::;::-:‘:—•：拉 j ‘ ： . ： “ liaiipfePSS�:、：.: J J -••‘ S 
. ；-,.，-•、•、,.- rj'.；-："'"‘ •‘ '•»•" •. . • • •.  ：：. .u：'；.• ； • j'：：-：*： •VA：；：： ；|：|：.-' . ：••，•.-•； • ... ••；,：.：；!»•；.- ；：•  ： •-.；；：：： 
-.::i”.鄉广‘M.�.，.�/:;:;:,' ...“ii'，::”々 :::；=:;•.、.• •：— ：.："•/.；〒”:〜：-；；>；；；；••• ‘•:：-•"::‘ .…"':“;;• 
T y p e o f e x p e r i m e n t(s) “沿 ’ ” ！： 、… ； 
AninuUexpcrimentusm^rats. I^oUolcohoI H^ be the h e p a t i c、： 
artery of the subject to induce embolization- - - … 、 《 
Place(s) where cxpcriment(s) may be conducted ^ " ' 一 � ‘ � � 
L« Hysan Clinical Research laboratory, 7/F, Clinical Sciencci Bldg: PWH - . 
Period of this authorization “ / 
r rooonoi To : 31.12.2002 ？ , � From ； 19.22U0I , , ' -
""""^^"isn""3SiSI]i3iil i i i!i i| i l i i i i i| iHI:S|::::�::: 
Conditions . �-. / . ： ； . • : . ； • • ： ： ： ； ： • ： , ;；「：“# ：：- • 
To study the effect of the embolization of hepatic artery with lipidol-alcohol on the fiinction of 
the liver on a n i i n d s . . 沿 • . ;：： '.ir^  iyiS 
. ..“..姊二：！^ 二： ：........;;;：;:;；：；"：：：：-".、：： 
Dated TlKNmetcenA^ ofFebruaxy2001«^ ^ 
......::«“..、.. • - . :;、1‘:丨.:‘.:;’:?‘：讓^ 
； . . . . … 厂 ： . ; . ' . — • ；：.  
m are commuted to provm叩 quaiify cikfit-0rU^mserv,嫩 
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r Fftrni 5� 
(to be endorsed on reverse of Fonii 2 or anachcd thereto) 
•• ；：：! ；：： • l.CJ" V • —：.；.：；：• ；-•«•! ••!： •*.；!：.•：•••• • • ： V ：•• • ；：• •• .V. . • ； .• ..... • • 
•••• , ：；• '".：：".^!；；：. -：'-；'.：{|,[；'； •• . … 一 广 • ： 二 二 , 广 [ : : • .;;-•.•：;.-• ： = ：•；. 
Endorsement lo Authorize Experiments w i f o u t ' � — -
Anaesthetics or without DesPoytng the Animal ‘ . 
_ • “.-..，叩.•'.�:.•”::;.�].:: J � : f : … 二 ; I T � … . . - ‘ ] ' ! ; ; : ! ： jii.^ ^ ：： ： "J 
.:.“::、.::• : ： ••：;•；; i . ， . ” . . ： . ' - : 二 二 ; : — — : ; i；；- ；:“ .：； ： ：； ： ••••• - •‘ 
..“;.••-”,，.,..：.. ：..，：'：'• - • .��.....•: p'r；； .-^''ft?'•‘•：.；•:?!；• • ’ ^ ' ： • “ ： • • • . • • ！'..>•:..::. ..-‘.： • i： ‘：A：：.；.S..“:.�.:;.• • /：：...：.：： . : . - ： •.：•. Name ： CHAN Tai-po -Address ： D e p a r t m e n t of Diagnostic Radiology & Organ Imaging. ’ , 
PWH : J.::-?:;.》.:.：. ‘ : .,-ti; 
- . " ' ' ： ‘ , • :；；• --WM- Xi ' ：• ^^  
By virtue ofscction 10 of the Animals (Control of Expcrim斤这)Otdmm ,^ Chapter 340 
the holder of ^ s Licence is b饥by authorised to perform the type ot expcnmenl(s) at the place(s) 
= subject to the conditions hereinafter mentioned, without adnumstratmg any ^ S tl^ii^ concerned or without kiUing the animal concerned before «recovers f^m 
the influence of any anaesthetic administered. 
• - • h--- •‘..".-‘ ::: • 時;;:，; 
‘ I ” •：,!；：；： ^； • . ； ; " i ^ . l ? " .,“.•• .-•?!!.:•:：：；；.、. irviVKi!::.'；：'':：-：!:--':； ：；-； • ； 
.…-:.、。;。：.. .、 , . . .-：；.：：.；., ：•• V：：. -•- .；：.；.：；-：;；：•,；*；•• •• ••；.,：：；； ••：.- •广：.. Typcafexpcriment(s) “ -
Animal experiment using r a t s . / L i p i d o l ^ a k o h d n i t o c w m be injected into the hepatic 
artexy o f the subject to induce embplizanon. ‘ w广、j ： 广 
— . :..,:、.. ;: ：: ： • 遍|_釋:;;__：隨. ： ：.,:.:: ： •:、:“:;口: 
Place(s) where experiment(s) may be conducted� � : “ �’：‘, 
Lcc Hysan Clinical Rcselrch l^ratory. 7/F, Clinical Sciences Bldg.�PWH 
Period of this permit 行 
… 侧 To : 31.122002 - ‘ From : 19.2.2001 • . 
Conditions ,’， ’ " 
To study . e f f e c t of the embolization ofhcparic artery with UpidoUaicphd on the function of 
the liver on animals. � 丨阳 / :•. 丨 
Dated The Nineteenth of Febnmry 2001 ‘ / 
；r： ’ 響 、 • 
供 a r c commiiied to providing quality client-oriented service 
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